Acuta Capital Partners, LLC Mereo Biopharma Group PLC Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 779,308 shares of MREO stock, worth $1.94 Million. This represents 3.88% of its overall portfolio holdings.
Number of Shares
779,308
Previous 1,260,700
38.18%
Holding current value
$1.94 Million
Previous $5.18 Million
47.37%
% of portfolio
3.88%
Previous 5.25%
Shares
4 transactions
Others Institutions Holding MREO
# of Institutions
99Shares Held
116MCall Options Held
151KPut Options Held
455K-
Janus Henderson Group PLC London, X017.1MShares$42.6 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$38.1 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$23.9 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$21.7 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$21.5 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $311M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...